BMC ophthalmology · 2025
CDK4/6 inhibitor-associated vortex keratopathy: a case report.
СтатьяКлинический случайНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shu Lian, Cui Xinhan, Wang Yan, Sun Xinghuai
Аннотация
BACKGROUND: Cyclin-dependent kinase (CDK) 4/6 inhibitors are novel anticancer drugs that can arrest the cell cycle and halt the progression of cancers. This study presents a rare case of vortex keratopathy associated with the use of a cyclin-dependent kinase (CDK) 4/6 inhibitor for breast cancer treatment.
PATIENT PRESENTATION: A 60-year-old female patient with a one-year history of eye irritation presented at our hospital. She had been diagnosed with metastatic breast cancer two years prior and received treatment with tiremciclib (a novel CDK4/6 inhibitor) in combination with fulvestrant at the same time. After slit-lamp examination, anterior segment optical coherence tomography (AS-OCT), and corneal confocal microscopy, the patient was diagnosed with vortex keratopathy. The ocular symptoms of the patient improved slightly after the use of artificial lubricating eye drops.
CONCLUSIONS: This case demonstrates the ocular characteristics and novel findings of corneal confocal microscopy of CDK4/6 inhibitor-related vortex keratopathy. Our findings increase the understanding of the pathophysiological mechanisms of drug-induced vortex keratopathy and increase our awareness of ocular manifestations in patients receiving novel anticancer drugs.
PATIENT PRESENTATION: A 60-year-old female patient with a one-year history of eye irritation presented at our hospital. She had been diagnosed with metastatic breast cancer two years prior and received treatment with tiremciclib (a novel CDK4/6 inhibitor) in combination with fulvestrant at the same time. After slit-lamp examination, anterior segment optical coherence tomography (AS-OCT), and corneal confocal microscopy, the patient was diagnosed with vortex keratopathy. The ocular symptoms of the patient improved slightly after the use of artificial lubricating eye drops.
CONCLUSIONS: This case demonstrates the ocular characteristics and novel findings of corneal confocal microscopy of CDK4/6 inhibitor-related vortex keratopathy. Our findings increase the understanding of the pathophysiological mechanisms of drug-induced vortex keratopathy and increase our awareness of ocular manifestations in patients receiving novel anticancer drugs.